Video

QUILT 3032 study shows efficacy of N-803 in BCG-unresponsive bladder cancer

Author(s):

Urology Times staff

“To have at the 2-year mark basically half the patients still without evidence of disease is really a step forward,” says Sam S. Chang, MD, MBA.

Sam S. Chang, MD, MBA, discusses results from the phase 2/3 QUILT-3.032 trial showing the efficacy of the combination of BCG and the novel interleukin-15 superagonist N-803 in patients with BCG-unresponsive bladder cancer.

Chang is a professor in the Department of Urology, Patricia and Rodes Hart Professor of Urologic Surgery, and chief surgical officer and chief of the Division of Urologic Oncology at Vanderbilt Ingram Cancer Center.

Related Videos
4 experts in this video
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Related Content
Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS
In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
May 12th 2025

Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

Hannah Clarke
The phase 3 RC48-C016 trial met its primary end points.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Artificial urinary sphincter for SUI shows safety, efficacy in prospective study
May 9th 2025

Artificial urinary sphincter for SUI shows safety, efficacy in prospective study

Melissa Kaufman, MD, PhD, FACS Hannah Clarke
"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.
Physical function and frailty measures offer distinct insights in patients with bladder cancer
May 7th 2025

Physical function and frailty measures offer distinct insights in patients with bladder cancer

Hannah Clarke
Data showed that physical function and self-reported frailty assessments were poorly correlated.
© 2025 MJH Life Sciences

All rights reserved.